A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Halperin, Daniel M ^a   Phan, Alexandria T ^b   Hoff, Ana O ^c   Aaron, Marie ^a   Yao, James C ^a   Hoff, Paulo M ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; DACARBAZINE; IMATINIB; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; DEOXYCYTIDINE; FLUOROURACIL; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ABDOMINAL DISTENSION; ADRENAL CORTEX CARCINOMA; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC RHINITIS; ALOPECIA; ANOREXIA; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER SURVIVAL; CHEST TIGHTNESS; CHILL; CLINICAL ARTICLE; CONSTIPATION; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG TOLERABILITY; DRY SKIN; DYSPHAGIA; DYSPNEA; EDEMA; ENDOCRINE TUMOR; EPIPHORA; EYE DISEASE; FATIGUE; FEMALE; FEVER; HAND FOOT SYNDROME; HEART MUSCLE ISCHEMIA; HEART PALPITATION; HEMOGLOBIN BLOOD LEVEL; HOT FLUSH; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; INSOMNIA; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MENTAL INSTABILITY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROENDOCRINE TUMOR; NEUROPATHY; NEUTROPHIL COUNT; OVERALL SURVIVAL; PAIN; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; RECOMMENDED DRUG DOSE; RIGOR; SENSORY NEUROPATHY; SIDE EFFECT; SINUS TACHYCARDIA; SOMNOLENCE; SWEATING; TASTE DISORDER; THROMBOCYTE; THROMBOCYTE COUNT; THYROID MEDULLARY CARCINOMA; TRANSITIONAL CELL CARCINOMA; UPPER RESPIRATORY TRACT INFECTION; VISUAL DISORDER; VOICE DISORDER; VOMITING; XEROSTOMIA; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; ENDOCRINE GLAND NEOPLASMS; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZAMIDES; CAPECITABINE; DACARBAZINE; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; ENDOCRINE GLAND NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; IMATINIB MESYLATE; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; TREATMENT OUTCOME;

EID: 84924804904     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-561     Document Type: Article

References (34)

1. Hazard JB, Hawk WA, Crile G. Medullary (solid) carcinoma of the thyroid: A clinicopathologic entity. J Clin Endocrinol Metab 1959, 19:152-161. 10.1210/jcem-19-1-152, 13620740.
2. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJ, Lombardi G, Mannelli M, Pacini F, Ponder BA, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells SA, Marx SJ. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001, 86(12):5658-5671. 10.1210/jcem.86.12.8070, 11739416.
3. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, Ponder MA, Telenius H, Tunnacliffe A, Ponder BAJ. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993, 363(6428):458-460. 10.1038/363458a0, 8099202.
4. Boccia LM, Green JS, Joyce C, Eng C, Taylor SA, Mulligan LM. Mutation of RET codon 768 is associated with the FMTC phenotype. Clin Genet 1997, 51(2):81-85.
5. Bolino A, Schuffenecker I, Luo Y, Seri M, Silengo M, Tocco T, Chabrier G, Houdent C, Murat A, Schlumberger M, Tourniaire J, Lenoir GM. RET mutations in exons 13 and 14 of FMTC patients. Oncogene 1995, 10(12):2415-2419.
6. Wohllk N, Cote GJ, Bugalho MM, Ordonez N, Evans DB, Goepfert H, Khorana S, Schultz P, Richards CS, Gagel RF. Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 1996, 81(10):3740-3745.
7. Eng C, Mulligan LM, Smith DP, Healey CS, Frilling A, Raue F, Neumann HP, Pfragner R, Behmel A, Lorenzo MJ, Stonehouse TJ, Ponder MA, Ponder BAJ. Mutation of the RET protooncogene in sporadic medullary thyroid carcinoma. Genes Chromosomes Cancer 1995, 12(3):209-212. 10.1002/gcc.2870120308, 7536460.
8. Hofstra RM, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, Pasini B, Hoppener JW, van Amstel HK, Romeo G, Lips CJM, Buys CHCM. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994, 367(6461):375-376. 10.1038/367375a0, 7906866.
9. Zedenius J, Larsson C, Bergholm U, Bovee J, Svensson A, Hallengren B, Grimelius L, Backdahl M, Weber G, Wallin G. Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab 1995, 80(10):3088-3090.
10. Asai N, Iwashita T, Matsuyama M, Takahashi M. Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol 1995, 15(3):1613-1619. 230385, 7532281.
11. Xing S, Smanik PA, Oglesbee MJ, Trosko JE, Mazzaferri EL, Jhiang SM. Characterization of ret oncogenic activation in MEN2 inherited cancer syndromes. Endocrinology 1996, 137(5):1512-1519.
12. Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH, Di Fiiore PP. Activation of RET as a dominant transforming gene by germline mutations of MEN 2A and MEN 2B. Science 1995, 267:381-383. 10.1126/science.7824936, 7824936.
13. Marshall GM, Peaston AE, Hocker JE, Smith SA, Hansford LM, Tobias V, Norris MD, Haber M, Smith DP, Lorenzo MJ, Ponder BA, Hancock JF. Expression of multiple endocrine neoplasia 2B RET in neuroblastoma cells alters cell adhesion in vitro, enhances metastatic behavior in vivo, and activates Jun kinase. Cancer Res 1997, 57(23):5399-5405.
14. Cohen MS, Hussain HB, Moley JF. Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors. Surgery 2002, 132(6):960-966. discussion 966-967, 10.1067/msy.2002.128562, 12490842.
15. Scherubl H, Raue F, Ziegler R. Combination chemotherapy of advanced medullary and differentiated thyroid cancer. Phase II study. J Cancer Res Clin Oncol 1990, 116(1):21-23. 10.1007/BF01612635, 2312602.
16. Wu LT, Averbuch SD, Ball DW, de Bustros A, Baylin SB, McGuire WP. Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine. Cancer 1994, 73(2):432-436. 10.1002/1097-0142(19940115)73:2<432::AID-CNCR2820730231>3.0.CO;2-K, 8293411.
17. Schlumberger M, Abdelmoumene N, Delisle MJ, Couette JE. Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs a Calcitonine (GETC). Br J Cancer 1995, 71(2):363-365. 10.1038/bjc.1995.73, 2033569, 7530987.
18. Di Bartolomeo M, Bajetta E, Bochicchio AM, Carnaghi C, Somma L, Mazzaferro V, Visini M, Gebbia V, Tumolo S, Ballatore P. A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) Group. Ann Oncol 1995, 6(1):77-79.
19. Bajetta E, Rimassa L, Carnaghi C, Seregni E, Ferrari L, Di Bartolomeo M, Regalia E, Cassata A, Procopio G, Mariani L. 5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. Cancer 1998, 83(2):372-378. 10.1002/(SICI)1097-0142(19980715)83:2<372::AID-CNCR23>3.0.CO;2-P, 9669822.
20. Petursson SR. Metastatic medullary thyroid carcinoma. Complete response to combination chemotherapy with dacarbazine and 5-fluorouracil. Cancer 1988, 62(9):1899-1903. 10.1002/1097-0142(19881101)62:9<1899::AID-CNCR2820620905>3.0.CO;2-C, 3167804.
21. Wells SA, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012, 30(2):134-141. 10.1200/JCO.2011.35.5040, 3675689, 22025146.
22. Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Muller T, Ratain MJ, Salgia R. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 2011, 29(19):2660-2666. 10.1200/JCO.2010.32.4145, 3646303, 21606412.
23. Dackiw AP, Lee JE, Gagel RF, Evans DB. Adrenal cortical carcinoma. World J Surg 2001, 25(7):914-926. 10.1007/s00268-001-0030-7, 11572033.
24. Kerkhofs TM, Verhoeven RH, Van der Zwan JM, Dieleman J, Kerstens MN, Links TP, Van de Poll-Franse LV, Haak HR. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer 2013, 49(11):2579-2586. 10.1016/j.ejca.2013.02.034, 23561851.
25. Soon PS, McDonald KL, Robinson BG, Sidhu SB. Molecular markers and the pathogenesis of adrenocortical cancer. Oncologist 2008, 13(5):548-561. 10.1634/theoncologist.2007-0243, 18515740.
26. Koch CA, Pacak K, Chrousos GP. The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors. J Clin Endocrinol Metab 2002, 87(12):5367-5384. 10.1210/jc.2002-021069, 12466322.
27. Hutter AM, Kayhoe DE. Adrenal cortical carcinoma. Results of treatment with o, p'DDD in 138 patients. Am J Med 1966, 41(4):581-592. 10.1016/0002-9343(66)90220-8, 5923599.
28. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B, Sorbye H, Torpy DJ, Stepan V, Schteingart DE, Arlt W, Kroiss M, Leboulleux S, Sperone P, Sundin A, Hermsen I, Hahner S, Willenberg HS, Tabarin A, Quinkler M, de la Fouchardiere C, Schlumberger M, Mantero F, Weismann D, Beuschlein F, Gelderblom H, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 2012, 366(23):2189-2197. 10.1056/NEJMoa1200966, 22551107.
29. Fraenkel M, Gueorguiev M, Barak D, Salmon A, Grossman AB, Gross DJ. Everolimus therapy for progressive adrenocortical cancer. Endocrine 2013, 44(1):187-192. 10.1007/s12020-013-9878-1, 23417626.
30. Berruti A, Sperone P, Ferrero A, Germano A, Ardito A, Priola AM, De Francia S, Volante M, Daffara F, Generali D, Leboulleux S, Perotti P, Baudin E, Papotti M, Terzolo M. Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. Eur J Endocrinol 2012, 166(3):451-458. 10.1530/EJE-11-0918, 22189997.
31. Kroiss M, Quinkler M, Johanssen S, van Erp NP, Lankheet N, Pollinger A, Laubner K, Strasburger CJ, Hahner S, Muller HH, Allolio B, Fassnacht M. Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. J Clin Endocrinol Metab 2012, 97(10):3495-3503. 10.1210/jc.2012-1419, 22837187.
32. Gross DJ, Munter G, Bitan M, Siegal T, Gabizon A, Weitzen R, Merimsky O, Ackerstein A, Salmon A, Sella A, Slavin S. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocr Relat Cancer 2006, 13(2):535-540. 10.1677/erc.1.01124, 16728580.
33. de Groot JW, Plaza Menacho I, Schepers H, Drenth-Diephuis LJ, Osinga J, Plukker JT, Links TP, Eggen BJ, Hofstra RM. Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations. Surgery 2006, 139(6):806-814. 10.1016/j.surg.2005.10.019, 16782438.
34. Frank-Raue K, Fabel M, Delorme S, Haberkorn U, Raue F. Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma. Eur J Endocrinol 2007, 157(2):215-220. 10.1530/EJE-06-0695, 17656601.